Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response contains one high-severity label-nonconforming indication claim (PONV). Several additional claims about typical patient information content are marked as absent from or insufficiently supported by the provided label sections, leading to overall partial alignment.
Category Scores
Accurate Statements
Akynzeo is used for prevention of chemotherapy-induced nausea and vomiting (CINV).
Supported by 1 INDICATIONS AND USAGE (prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy in combination with dexamethasone in adults).
Patient product information for medicines like Akynzeo typically covers serious warning signs that require urgent medical attention.
Supported by 17 PATIENT COUNSELING INFORMATION and 5 WARNINGS AND PRECAUTIONS (e.g., immediate medical attention for hypersensitivity reactions; serotonin syndrome symptoms requiring immediate attention).
Patient product information usually includes general medication safety warnings, including guidance on allergic reactions and symptoms that should prompt immediate medical care.
Supported by 17 PATIENT COUNSELING INFORMATION and 5.1 Hypersensitivity (seek immediate medical attention for signs/symptoms of hypersensitivity reactions including anaphylaxis).
Unsupported Statements
Patient product information for Akynzeo typically includes an Instructions for Use/Medication Guide-style document.
The provided label excerpts do not support existence or typical inclusion of an Instructions for Use/Medication Guide-style document.
Patient product information for medicines like Akynzeo typically covers what symptoms it is meant to prevent.
Not supported by the provided 17 PATIENT COUNSELING INFORMATION excerpt.
Patient product information for medicines like Akynzeo typically covers common side effects (and what to do about them).
Not supported by the provided 17 PATIENT COUNSELING INFORMATION excerpt.
Patient product information for medicines like Akynzeo typically covers interactions and contraindications.
The provided label excerpts do not support that patient information typically covers interactions and contraindications; contraindications are listed as none in 4 CONTRAINDICATIONS.
Patient product information usually highlights expected nausea/vomiting-related effects.
Not supported by the provided 17 PATIENT COUNSELING INFORMATION excerpt.
Contradictions
High
AI Statement
Akynzeo is used for prevention of postoperative nausea and vomiting (PONV).
Label Reference
1 INDICATIONS AND USAGE (label excerpt provided addresses nausea and vomiting associated with cancer chemotherapy; no PONV indication provided).
Important Omissions
The label supports specific administration timing for AKYNZEO capsules (~1 hour prior to start of chemotherapy), but the response does not clearly anchor its general 'how to take it' claims to this timing detail.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The incorrect indication claim for PONV could lead to inappropriate use relative to the provided label indications. Other unsupported claims are primarily informational about patient materials content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
PONV indication claim is nonconforming with the provided label indications.
Suggested Improvement
Remove/replace the PONV claim. Limit statements about typical patient information content to what is explicitly supported by the provided 17 PATIENT COUNSELING INFORMATION excerpt (e.g., administration timing and specific warning/seek-care guidance for hypersensitivity and serotonin syndrome).